Sugi Predict

Sugi Predict / Compounds / SCHEMBL246415

SCHEMBL246415

SCHEMBL246415

CCCC[Sn](CCCC)(CCCC)c1cccc(C)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CCR1 P32246 1/20 0.39
▸ CCR8 P51685 1/20 0.39
▸ NOS3 P29474 1/20 0.36
▸ NOS2 P35228 1/20 0.36
▸ KCNH2 Q12809 1/20 0.36
▸ RAB9A P51151 5/20 0.35
▸ NPC1 O15118 4/20 0.35
▸ HSD17B10 Q99714 2/20 0.35
▸ SMN1; SMN2 Q16637 2/20 0.35
▸ LMNA P02545 1/20 0.35
▸ TP53 P04637 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ GRM5 P41594 4/20 0.33
▸ TLR8 Q9NR97 1/20 0.33
▸ P2RX7 Q99572 1/20 0.33
▸ MEN1 O00255 2/20 0.32
▸ KMT2A Q03164 2/20 0.32
▸ NPSR1 Q6W5P4 2/20 0.32
▸ NR4A2 P43354 1/20 0.31
▸ GAA P10253 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29865866 1.00 CCR1 (0.39) CCR1CCR8NOS3NOS2KCNH2
SCHEMBL29851343 0.92 CCR1 (0.33) CCR1CCR8NOS3NOS2KCNH2
SCHEMBL3748371 0.83 KCNH2 (0.37) CCR1CCR8KCNH2TLR8
SCHEMBL2721185 0.81 KCNH2 (0.33) KCNH2
SCHEMBL30070612 0.80 KCNH2 (0.35) KCNH2
SCHEMBL1143101 0.80 KCNH2 (0.35) KCNH2
SCHEMBL12615482 0.80 KCNH2 (0.35) KCNH2
SCHEMBL2650003 0.80 KCNH2 (0.35) KCNH2SMN1; SMN2MAPTNPSR1NR4A2
SCHEMBL29851211 0.80 KCNH2 (0.35) KCNH2SMN1; SMN2MAPTNPSR1NR4A2
SCHEMBL29851025 0.80 KCNH2 (0.35) KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 233 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4142732-B1 METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS GLOBAL BLOOD THERAPEUTICS INC (US) 2026-04-22 — — EP disclosed
US-12522582-B2 Antiviral indolinyl compounds and uses thereof GILEAD SCIENCES, INC. (US) 2026-01-13 — — US disclosed
EP-4619099-A1 PYRIDO OXAZOLIDINONE DERIVATIVES AS ALK5 INHIBITORS Chiesi Farmaceutici S.p.A. (IT) 2025-09-24 — — EP disclosed
US-12378254-B2 Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators JANSSEN PHARMACEUTICA NV (BE) 2025-08-05 — — US disclosed
US-20250109122-A1 CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS GLOBAL BLOOD THERAPEUTICS INC (US) 2025-04-03 — — US disclosed
EP-4526289-A1 ANTIVIRAL INDOLINYL COMPOUNDS AND USES THEREOF GILEAD SCIENCES, INC. (US) 2025-03-26 — — EP disclosed
CN-119546574-A Antiviral indolinyl compounds and uses thereof 吉利德科学公司 2025-02-28 — — CN disclosed
US-12202817-B2 Cycloalkyl pyrimidines as ferroportin inhibitors GLOBAL BLOOD THERAPEUTICS, INC. (US) 2025-01-21 — — US disclosed
EP-3676261-B1 SUBSTITUTED 2-AZABICYCLO[3.1.1]HEPTANE AND 2-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS CHRONOS THERAPEUTICS LTD (GB) 2024-12-18 — — EP disclosed
EP-3492461-B1 NITROGENOUS HETEROCYCLIC AROMATIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATION THEREOF SHANGHAI YINGLI PHARM CO LTD (CN) 2024-10-23 — — EP disclosed
WO-2007014922-A1 MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS TIBOTEC PHARMACEUTICALS LTD. (IE) 2007-02-08 — — WO disclosed
EP-1697344-A2 HIV PROTEASE INHIBITING COMPOUNDS ABBOTT LABORATORIES (US) 2006-09-06 — — EP disclosed
EP-1689376-A2 DIARYL UREA DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES Novartis AG (CH) 2006-08-16 — — EP disclosed
US-20050148623-A1 Prevent reproduct of aids virus ABBVIE INC. 2005-07-07 — — US disclosed
WO-2005058841-A2 HIV PROTEASE INHIBITING COMPOUNDS ABBOTT LABORATORIES (US) 2005-06-30 — — WO disclosed
US-20050131017-A1 HIV protease inhibiting compounds ABBOTT LABORATORIES 2005-06-16 — — US disclosed
WO-2005051366-A2 DIARYL UREA DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES NOVARTIS AG (CH) 2005-06-09 — — WO disclosed
US-6747023-B1 INHIBITORS FOR ACTIVATED COAGULATION FACTOR X, COAGULATION SUPPRESSORS DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-06-08 — — US disclosed
US-20040082611-A1 Anticoagulants; brain disorders; respiratory system disorders; side effect reduction DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-04-29 — — US disclosed
EP-1104754-A1 NOVEL SULFONYL DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2001-06-06 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050148623-A1 Prevent reproduct of aids virus SERPINB1, PRSS1, SERPINA3 CCR1 1559/4885CCR8 1924/4885NOS3 1489/4885
US-12202817-B2 Cycloalkyl pyrimidines as ferroportin inhibitors HAMP, SLC40A1, FANCI CCR1 940/4885CCR8 1412/4885NOS3 3070/4885
US-20040082611-A1 Anticoagulants; brain disorders; respiratory system disorders; side effect reduction F2, CYC1, SULT2A1 CCR1 2561/4885CCR8 4481/4885NOS3 2113/4885
US-12378254-B2 Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators HCRTR2, HCRTR1, OXTR CCR1 894/4885CCR8 1668/4885NOS3 1357/4885
US-20050131017-A1 HIV protease inhibiting compounds SERPINB1, HPN, DNPEP CCR1 2263/4885CCR8 2084/4885NOS3 1993/4885
US-20250109122-A1 CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS HAMP, SLC40A1, FANCI CCR1 940/4885CCR8 1412/4885NOS3 3070/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.